GeNeuro S.A. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
3,182.80
7,856.60
19,560.20
34,489.40
26,600.00
Total Accounts Receivable
718.80
990.40
749.90
679.70
-
Other Current Assets
42.20
42.80
235.40
765.50
-
Total Current Assets
3,943.80
8,889.80
20,545.50
35,934.60
-
Net Property, Plant & Equipment
76.70
37.70
67.20
153.70
-
Total Investments and Advances
-
-
-
537.70
-
Long-Term Note Receivable
-
-
-
53.50
-
Intangible Assets
122.20
124.80
145.40
1,101.30
-
Total Assets
4,203.80
9,066.50
20,763.60
37,780.80
-
ST Debt & Current Portion LT Debt
310.90
-
-
21.80
-
Accounts Payable
411.40
1,034.20
1,884.50
3,031.60
-
Other Current Liabilities
306.50
1,030.80
6,470.10
9,501.80
-
Total Current Liabilities
1,028.80
2,065.00
8,354.60
12,555.20
-
Long-Term Debt
176.20
169.40
176.20
161.50
-
Provision for Risks & Charges
282.40
581.70
977.50
1,062.20
-
Deferred Taxes
53.30
4.00
5.50
-
-
Other Liabilities
-
-
9,560.90
5,333.60
-
Total Liabilities
1,495.20
2,826.30
19,069.20
19,112.50
-
Common Equity (Total)
2,708.60
6,240.20
1,694.40
18,668.30
-
Total Shareholders' Equity
2,708.60
6,240.20
1,694.40
18,668.30
-
Total Equity
2,708.60
6,240.20
1,694.40
18,668.30
-
Liabilities & Shareholders' Equity
4,203.80
9,066.50
20,763.60
37,780.80
-

About GeNeuro

View Profile
Address
3, Chemin du Pré-Fleuri
Plan-les-Ouates Geneve (Geneva) 1228
Switzerland
Employees -
Website http://www.geneuro.ch/fr/accueil
Updated 07/08/2019
GeNeuro SA engages in the research and development of pharmaceutical products. It offers GNbAC1, a therapeutic antibody that targets MSRV-Env. It also offers a drug for multiple sclerosis.